Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1873-1881

  Gladstone, Douglas E ^a   Swinnen, Lode ^a   Kasamon, Yvette ^a   Blackford, Amanda ^a   Gocke, Christopher D ^a   Griffin, Constance A ^a   Meade, Javier Bolanos ^a   Jones, Richard J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

clinical outcomes; CLL; del(13q); IGHV; overall survival

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE FREE SURVIVAL; FOLLOW UP; GENE DELETION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; FOLLOW-UP STUDIES; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 80053206498     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.585529     Document Type: Article

References (23)

1. Dighiero G. Unsolved issues in CLL biology and management. Leukemia 2003;17:2385-2391. (Pubitemid 38072576)
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
3. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986;62: 567-575. (Pubitemid 16130192)
4. Codony C, Crespo M, Abrisqueta P, Montserrat E, Bosch F. Gene expression profiling in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2009;22:211-222.
5. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916. (Pubitemid 32064784)
6. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121:287-295. (Pubitemid 36560596)
7. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634-4641. (Pubitemid 46630962)
8. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363-372.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348: 1764-1775. (Pubitemid 36514707)
10. Marjanovic G, Stanojevic I, Jankovic-Velickovic L, Hubl W, Marjanovic V. Detection of ZAP-70 in patients with chronic lymphocytic leukemia. J BUON 2008;13:543-546.
11. Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 2009;14:101-105.
12. Gattei V, Bulian P, DelPrincipe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865-873.
13. Carlucci F, Marinello E, Tommassini V, Pisano B, Rosi F, Tabucchi A. A 57-gene expression signature in B-cell chronic lymphocytic leukemia. Biomed Pharmacother 2009;63:663-671.
14. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854. (Pubitemid 29430400)
15. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-1029. (Pubitemid 34525567)
16. Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. Chronic lymphocytic leukemia FISH panel: impact on diagnosis. Am J Clin Pathol 2007;128: 323-332. (Pubitemid 47262633)
17. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-1416. (Pubitemid 34864299)
18. Van Dyke DL, Shanafelt TD, Call TG, et al. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2010;148:544-550.
19. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
20. Kharfan-Dabaja MA, Chavez JC, Khorfan KA, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 2008;113:897-906.
21. Trojani A, Montillo M, Nichelatti M, et al. ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia. Cancer Biomark 2010;6:1-9.
22. Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol 2008;140:320-323.
23. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-1409. (Pubitemid 34864298)